A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With Type-2 Diabetes (T2D)
A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With Type-2 Diabetes (T2D)
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight with type 2 diabetes.
Participation in the study will last about 11 months.
Inclusion Criteria:
W8M-MC-GN02:
W8M-MC-CWMM:
Exclusion Criteria:
W8M-MC-GN02:
Individuals who are of childbearing potential
Have a history of acute or chronic pancreatitis
Have any of the following cardiovascular conditions within 6 months prior to screening:
W8M-MC-CWMM:
Troy, Michigan 48098, United States
Wenatchee, Washington 98801, United States
Buenos Aires, Buenos Aires F.D. C1425AGC, Argentina